Company intelligence / Profile preview

Husoh

Lianyungang, Jiangsu, China

Ownership: Private
Employees: ~3000
Development stage: Other

Overview

Hansoh has 7 approved innovative drugs and more than 40 clinical candidates across oncology, anti-infectives, CNS, metabolic, and autoimmune diseases. Several agents are first-in-class or best-in-class in China, and partnerships have expanded their reach internationally. Recent highlights include a robust ADC pipeline and multiple deals with companies like GSK and Biotheus.

Therapeutic areas: ImmunologyNephrologyEndocrinologyMetabolic DisordersInfectious DiseasesOncologyNeurology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateSiRNASynthetic peptideBispecific monoclonal antibodyBiologic
Industry: Biotech

Partnerships

GSKMSDRegeneronBiotheusMultiple in-licensing and out-licensing agreements

Beyond the preview

Go deeper on Husoh.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Husoh.

Explore the full profile